At the 11th All-Russian GMP Conference, Chinara Mambetalieva set out the figures of the Eurasian medicines registration and inspection system and the main changes for 2026. Source: Eurasian Economic Commission (EEC).
The package updates Annex 1 to the GMP rules, adds Part 4 with specific requirements for high-technology medicines, and adopts guidance on temperature mapping and microbiological monitoring.
She also highlighted EEC Council Decision No. 87 of 9 July 2026, which requires competent authorities of Union countries to apply WHO good regulatory practices (GRP). Unlike GMP, which speaks to the manufacturer, GRP describes how the regulator is organised, how decisions are prepared and how their impact is assessed.
On the sidelines, a working group on pharmaceutical inspections for good practices in EAEU medicines circulation met away from its usual venue, with inspectorates of the member states.
This year’s conference programme covers GMP changes, contract manufacturing, biologics, licensing, inspections and the Union’s common market. Participants include regulators, expert bodies and manufacturers from EAEU states, plus experts from South Africa, Indonesia and the African Medicines Agency.
